DAVID JAY COHEN
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- MACON, GA
- NPI
- 1487652020
- Received
- $2,886,898 in 3,526 records, 2019 to 2025 ($2,868,089 general, $18,809 research)
- As principal investigator
- $2,652,951 of research payments to others in 498 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 558 | $540,258 |
| 2024 | General payment | 594 | $449,437 |
| 2023 | General payment | 571 | $438,339 |
| 2022 | General payment | 517 | $407,009 |
| 2022 | Research payment | 2 | $480 |
| 2021 | General payment | 445 | $382,319 |
| 2021 | Research payment | 3 | $1,652 |
| 2020 | General payment | 216 | $158,352 |
| 2020 | Research payment | 7 | $3,012 |
| 2019 | General payment | 607 | $492,370 |
| 2019 | Research payment | 6 | $13,664 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 670 | $2,186,229 |
| Travel and Lodging | 817 | $326,936 |
| Honoraria | 30 | $135,680 |
| Consulting Fee | 44 | $107,083 |
| Food and Beverage | 1,917 | $78,447 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 6 | $22,000 |
| Research payment | 18 | $18,809 |
| Compensation for serving as faculty or as a speaker for a medical education program | 3 | $10,826 |
| Education | 21 | $884 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | ABBVIE INC. | $3,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-19 | Regeneron Healthcare Solutions, Inc. | $20 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-12-17 | UCB, Inc. | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-17 | UCB, Inc. | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,440 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-12-17 | UCB, Inc. | $81 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-17 | UCB, Inc. | $72 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-17 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-16 | GENZYME CORPORATION | $8,967 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-16 | GENZYME CORPORATION | $1,705 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-16 | GENZYME CORPORATION | $224 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-16 | GENZYME CORPORATION | $75 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-16 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-11 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-11 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-09 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | Incyte Corporation | $22 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-12-08 | UCB, Inc. | $5 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-07 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-05 | Janssen Biotech, Inc. | $31 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-05 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-05 | Janssen Pharmaceuticals, Inc | $13 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-04 | ABBVIE INC. | $3,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-04 | Galderma Laboratories, L.P. | $15 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-03 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-03 | ABBVIE INC. | $3,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-03 | SUN PHARMACEUTICAL INDUSTRIES INC. | $16 | Food and Beverage | In-kind items and services | Odomzo Drug, Oncology | 2025 | |
| 2025-11-26 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-26 | Lilly USA, LLC | $81 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-25 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-24 | Lilly USA, LLC | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-24 | Lilly USA, LLC | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-24 | ABBVIE INC. | $96 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-24 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-11-24 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-21 | ABBVIE INC. | $44 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-20 | ABBVIE INC. | $947 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-20 | ABBVIE INC. | $695 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-20 | ABBVIE INC. | $166 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-20 | Lilly USA, LLC | $84 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | ABBVIE INC. | $60 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-19 | Organogenesis Inc. | $46 | Food and Beverage | In-kind items and services | NUSHIELD Medical Supply, WOUND CARE | 2025 | |
| 2025-11-19 | LEO Pharma Inc. | $18 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-18 | Amgen Inc. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-18 | Amgen Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-18 | Amgen Inc. | $72 | Travel and Lodging | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-17 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-14 | Galderma Laboratories, L.P. | $5,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-12 | Galderma Laboratories, L.P. | $109 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-12 | Lilly USA, LLC | $20 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-12 | Galderma Laboratories, L.P. | $17 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-10 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-10 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-08 | Janssen Biotech, Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-07 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-06 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | Janssen Biotech, Inc. | $1,187 | Travel and Lodging | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-06 | Janssen Biotech, Inc. | $121 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-06 | Regeneron Healthcare Solutions, Inc. | $34 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-06 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-05 | Galderma Laboratories, L.P. | $1,062 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-05 | Galderma Laboratories, L.P. | $30 | Travel and Lodging | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-03 | Novartis Pharmaceuticals Corporation | $107 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-03 | Janssen Biotech, Inc. | $23 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-03 | Galderma Laboratories, L.P. | $19 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-31 | Lilly USA, LLC | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-31 | Lilly USA, LLC | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-31 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-30 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-29 | Janssen Biotech, Inc. | $8 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-28 | Lilly USA, LLC | $124 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-28 | Incyte Corporation | $28 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-27 | Galderma Laboratories, L.P. | $14 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $34 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Sanara MedTech Inc. | $19 | Food and Beverage | Cash or cash equivalent | CellerateRX Device, Collagen based wound filler | 2025 | |
| 2025-10-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | $123 | Travel and Lodging | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-23 | Organogenesis Inc. | $35 | Food and Beverage | In-kind items and services | SIMPLIMAX Medical Supply, WOUND CARE | 2025 | |
| 2025-10-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | $15 | Travel and Lodging | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-22 | Incyte Corporation | $1,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-20 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-18 | Janssen Biotech, Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $1,283 | Travel and Lodging | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $81 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-16 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-16 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-15 | Incyte Corporation | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-14 | Lilly USA, LLC | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-14 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-13 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-13 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-10-10 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-10 | Organon Llc | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-09 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-09 | Galderma Laboratories, L.P. | $2 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-08 | Incyte Corporation | $3,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-08 | Incyte Corporation | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-08 | ABBVIE INC. | $78 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-08 | ABBVIE INC. | $78 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-08 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,415 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $486 | Travel and Lodging | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $169 | Travel and Lodging | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $166 | Travel and Lodging | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $158 | Travel and Lodging | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $113 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-07 | Novartis Pharmaceuticals Corporation | $33 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-03 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-03 | Incyte Corporation | $270 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-02 | Incyte Corporation | $223 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $95 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-01 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-01 | Arcutis Biotherapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-30 | Incyte Corporation | $127 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-09-30 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-30 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-29 | PFIZER INC. | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8 | Food and Beverage | In-kind items and services | Winlevi Drug, Dermatology | 2025 | |
| 2025-09-27 | Janssen Biotech, Inc. | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-26 | Galderma Laboratories, L.P. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-26 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-25 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-25 | Janssen Biotech, Inc. | $121 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-25 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-24 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-22 | ABBVIE INC. | $370 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-22 | ABBVIE INC. | $235 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-22 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-18 | ABBVIE INC. | $786 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-18 | ABBVIE INC. | $476 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-18 | ABBVIE INC. | $141 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-18 | ABBVIE INC. | $119 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-18 | UCB, Inc. | $75 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-17 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-17 | ABBVIE INC. | $3,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-17 | Amgen Inc. | $87 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-17 | Janssen Biotech, Inc. | $26 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | $19 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-09-17 | Janssen Biotech, Inc. | $5 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-16 | LEO Pharma Inc. | $16 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-09-16 | UCB, Inc. | $8 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-15 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-09-11 | ABBVIE INC. | $983 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-11 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-11 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-10 | ABBVIE INC. | $139 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-10 | Lilly USA, LLC | $30 | Food and Beverage | In-kind items and services | EBGLYSS Drug, Immunology | 2025 | |
| 2025-09-10 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-09 | UCB, Inc. | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-09 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-09-09 | UCB, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-08 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-05 | ABBVIE INC. | $265 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-05 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-04 | GENZYME CORPORATION | $6,832 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-04 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-04 | Janssen Biotech, Inc. | $145 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-04 | GENZYME CORPORATION | $134 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-04 | GENZYME CORPORATION | $104 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-04 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-03 | Galderma Laboratories, L.P. | $150 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-30 | Janssen Biotech, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-27 | Lilly USA, LLC | $78 | Food and Beverage | In-kind items and services | EBGLYSS Drug, Immunology | 2025 | |
| 2025-08-26 | UCB, Inc. | $124 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-25 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-23 | Janssen Biotech, Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-23 | Janssen Biotech, Inc. | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-22 | Galderma Laboratories, L.P. | $3,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-22 | Galderma Laboratories, L.P. | $24 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $2,680 | Travel and Lodging | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $194 | Travel and Lodging | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $143 | Travel and Lodging | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $125 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-20 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-20 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-19 | ABBVIE INC. | $5,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-19 | ABBVIE INC. | $1,011 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-19 | ABBVIE INC. | $115 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-19 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-18 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-15 | Galderma Laboratories, L.P. | $15 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-14 | Galderma Laboratories, L.P. | $128 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | $11 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-13 | Arcutis Biotherapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-13 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-13 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-12 | GENZYME CORPORATION | $4,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-12 | GENZYME CORPORATION | $123 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-11 | Organon Llc | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-07 | Incyte Corporation | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-07 | ABBVIE INC. | $160 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 |
The latest 200 records of 3,526.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $3,519 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of | 2025 |
| 2025-12-08 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $21,489 | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St | 2025 |
| 2025-12-04 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $695 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-12-01 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,665 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-11-17 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $7,920 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of | 2025 |
| 2025-10-27 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $11,478 | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St | 2025 |
| 2025-10-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $107 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,907 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-10-03 | Novartis Pharmaceuticals Corporation | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,016 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety o | 2025 |
| 2025-10-02 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $1,390 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | 2025 |
| 2025-09-04 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,509 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-09-04 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,875 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-09-03 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $27,759 | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St | 2025 |
| 2025-08-14 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $722 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-08-11 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $10,423 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2025 |
| 2025-08-04 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $3,826 | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St | 2025 |
| 2025-07-17 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $807 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-07-14 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $9,758 | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St | 2025 |
| 2025-07-14 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $7,853 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2025 |
| 2025-06-12 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $438 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2025 |
| 2025-06-09 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $9,556 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2025 |
| 2025-05-19 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $25,423 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2025 |
| 2025-05-15 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,045 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $3,105 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $232 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,000 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-04-23 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,500 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-04-15 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,614 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-04-09 | Novartis Pharmaceuticals Corporation | DERMATOLOGIC SURGERY SPECIALISTS PC | $874 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety o | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $12,399 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $10,800 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of | 2025 |
| 2025-03-31 | Novartis Pharmaceuticals Corporation | DERMATOLOGIC SURGERY SPECIALISTS PC | $59,849 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety o | 2025 |
| 2025-03-27 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,132 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-03-11 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,207 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-03-10 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $32,185 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2025 |
| 2025-03-06 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $1,131 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | 2025 |
| 2025-03-06 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $6,000 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | 2025 |
| 2025-03-06 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $2,074 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | 2025 |
| 2025-03-03 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $3,212 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | 2025 |
| 2025-02-25 | Eli Lilly and Company | DERMATOLOGIC SURGICAL SPECIALISTS | $9,375 | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODER | 2025 |
| 2025-02-25 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,541 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-02-24 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $14,743 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2025 |
| 2025-02-20 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-02-18 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $12,300 | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension St | 2025 |
| 2025-01-17 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,961 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-01-07 | Eli Lilly and Company | DERMATOLOGIC SURGICAL SPECIALISTS | $5,517 | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS | 2025 |
| 2025-01-07 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $161 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2025 |
| 2025-01-07 | Eli Lilly and Company | DERMATOLOGIC SURGICAL SPECIALISTS | $10,751 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK | 2025 |
| 2024-12-23 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,542 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-12-16 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $27,604 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2024 |
| 2024-12-10 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,064 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-12-03 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,422 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-12-02 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,667 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-11-19 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,218 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-11-12 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $4,470 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2024 |
| 2024-11-12 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $165 | CNTO1959PSO3018 | 2024 |
| 2024-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | DERMATOLOGIC SURGERY SPECIALISTS | $2,500 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 |
| 2024-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | DERMATOLOGIC SURGERY SPECIALISTS | $1,500 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 |
| 2024-11-06 | Takeda Pharmaceuticals U.S.A., Inc. | DERMATOLOGIC SURGERY SPECIALISTS | $3,500 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 |
| 2024-10-10 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $430 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-10-04 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,289 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-09-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-09-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,180 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-09-18 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $2,707 | CNTO1959PSO3018 | 2024 |
| 2024-09-10 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $884 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-08-30 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $165 | CNTO1959PSO3018 | 2024 |
| 2024-08-19 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $776 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-08-19 | Eli Lilly and Company | DERMATOLOGIC SURGICAL SPECIALISTS | $6,982 | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODER | 2024 |
| 2024-08-13 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $538 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-08-12 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $1,945 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2024 |
| 2024-08-01 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $3,854 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-08-01 | Takeda Pharmaceuticals U.S.A., Inc. | DERMATOLOGIC SURGERY SPECIALISTS | $3,546 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 |
| 2024-07-12 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $21,948 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-07-10 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $3,983 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-07-08 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $10,268 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2024 |
| 2024-07-05 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $24,370 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 |
| 2024-07-01 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,990 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-07-01 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $2,474 | CNTO1959PSO3018 | 2024 |
| 2024-06-25 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,126 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-06-03 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,658 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-05-28 | Eli Lilly and Company | DERMATOLOGIC SURGICAL SPECIALISTS | $54 | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS | 2024 |
| 2024-05-20 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-05-10 | Janssen Research & Development, LLC | Dermatologic Surg Specialists PC | $165 | CNTO1959PSO3018 | 2024 |
| 2024-05-01 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,745 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-04-29 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $5,213 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-04-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-04-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-04-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-04-18 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $398 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2024 |
| 2024-04-16 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $668 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-04-04 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,210 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-03-26 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $53 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-03-19 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $484 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-03-12 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $3,606 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-03-07 | Galderma Laboratories, L.P. | Skin Care Physicians Of Georgia | $2,355 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With M | 2024 |
| 2024-03-04 | SANOFI US SERVICES INC. | Skin Care Physicians Of Georgia | $10,300 | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | 2024 |
| 2024-02-29 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $2,536 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-02-23 | Janssen Research & Development, LLC | DERMATOLOGIC SURGERY SPECIALISTS PC | $1,911 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2024 |
| 2024-02-13 | Regeneron Pharmaceuticals, Inc. | DERMATOLOGIC SURGERY SPECIALISTS PC | $940 | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2024 |
| 2024-02-09 | Takeda Pharmaceuticals U.S.A., Inc. | DERMATOLOGIC SURGERY SPECIALISTS DBA SKIN CARE PHYSICIANS OF GEORGIA | $2,975 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Macon-Bibb County, GA, county Bibb County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Macon-Bibb County, GA | County Bibb County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 156,578 | 156,578 | 10,940,407 |
| Population, 2020 census P1 | 157,346 | 157,346 | 10,711,908 |
| Median age B01002 | 36.8 | 36.8 | 37.6 |
| Under 18 B01001 | 24.4% | 24.4% | 23.2% |
| 65 and over B01001 | 16.4% | 16.4% | 15.0% |
| Households B11001 | 59,921 | 59,921 | 4,074,366 |
| Foreign born B05002 | 3.8% | 3.8% | 11.2% |
| Median household income B19013 | $51,234 | $51,234 | $77,353 |
| Median family income B19113 | $67,615 | $67,615 | $93,754 |
| Per capita income B19301 | $31,699 | $31,699 | $40,924 |
| Poverty rate B17001 | 24.7% | 24.7% | 13.4% |
| Unemployment rate B23025 | 8.1% | 8.1% | 5.1% |
| Civilian labor force B23025 | 69,087 | 69,087 | 5,496,061 |
| Mean commute (minutes) B08013 | 22.2 | 22.2 | 28.3 |
| Bachelor's degree or higher B15003 | 26.3% | 26.3% | 34.9% |
| Housing units B25001 | 71,962 | 71,962 | 4,541,835 |
| Owner-occupied B25003 | 51.4% | 51.4% | 65.7% |
| Renters B25003 | 48.6% | 48.6% | 34.3% |
| Median home value B25077 | $174,500 | $174,500 | $303,300 |
| Median gross rent B25064 | $1,066 | $1,066 | $1,393 |
| White, not Hispanic B03002 | 34.3% | 34.3% | 49.1% |
| Black B03002 | 54.7% | 54.7% | 30.7% |
| Hispanic or Latino B03002 | 4.7% | 4.7% | 11.0% |
| Asian B03002 | 2.3% | 2.3% | 4.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Macon-Bibb County, GA.
Comments